TERT-TP53 Mutations: a Novel Biomarker Pair for Hepatocellular Carcinoma Recurrence and Prognosis

Overview

Journal Sci Rep

Date 2025 Jan 29

PMID 39880909

Authors

Jin Li

Ling Bai

Zhaodan Xin

Jiajia Song

Hao Chen

Xingbo Song

Juan Zhou

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, and ranks among the most lethal malignancies globally, primarily due to its high rates of recurrence and metastasis. Despite the urgency, no reliable biomarkers currently exist for predicting tumor recurrence in HCC. Telomerase reverse transcriptase (TERT) promoter mutations (TERTpm) and cellular tumor antigen p53 mutations (TP53m) have been frequently documented in HCC, but their combined clinical significance remains undefined. In this study, we investigated the clinical implications of TERTpm, TP53m, and their co-occurrence in 50 HCC tissue samples using the next-generation sequencing (NGS) technology. We identified TERTpm (C228T) and TP53m in 16 (32%) and 24 (48%) samples, respectively. Our findings indicate that these mutations are more prevalent in male patients (100% for TERTpm, 83.33% for TP53m), in those with solitary tumors (87.5% for both), in individuals with G2-G3 hepatitis (100% / 83.3%), and in cases of moderately differentiated tumors (75.0% / 83.3%). Furthermore, patients with both TERTpm and TP53m exhibited a significantly higher risk of tumor relapse (P < 0.05) and shorter progression-free survival (P < 0.05). Collectively, our results suggest that presence of both TERTpm and TP53m may serve as a robust predictor of tumor recurrence and a marker of poor prognosis in HCC.

References

Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Nault J, Martin Y, Caruso S, Hirsch T, Bayard Q, Calderaro J . Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology. 2019; 71(1):164-182. DOI: 10.1002/hep.30811. View

Long J, Wang A, Bai Y, Lin J, Yang X, Wang D . Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019; 42:363-374. PMC: 6491941. DOI: 10.1016/j.ebiom.2019.03.022. View

Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L . Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol. 2023; 9(4):465-472. PMC: 9951101. DOI: 10.1001/jamaoncol.2022.7826. View

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y . Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Target Ther. 2024; 9(1):149. PMC: 11189549. DOI: 10.1038/s41392-024-01848-7. View

Carneiro M, de Castro I, Ferreira M . Telomeres in aging and disease: lessons from zebrafish. Dis Model Mech. 2016; 9(7):737-48. PMC: 4958310. DOI: 10.1242/dmm.025130. View

Xin Z, Li J, Zhang H, Zhou Y, Song J, Chen P . Cancer Genomic Alterations Can Be Potential Biomarkers Predicting Microvascular Invasion and Early Recurrence of Hepatocellular Carcinoma. Front Oncol. 2022; 12:783109. PMC: 8828586. DOI: 10.3389/fonc.2022.783109. View

10.

Liu Y, Su Z, Tavana O, Gu W . Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. 2024; 42(6):946-967. PMC: 11190820. DOI: 10.1016/j.ccell.2024.04.009. View

11.

Elliott K, Singh V, Backerholm A, Ogren L, Lindberg M, Soczek K . Mechanistic basis of atypical TERT promoter mutations. Nat Commun. 2024; 15(1):9965. PMC: 11574208. DOI: 10.1038/s41467-024-54158-5. View

12.

Zheng L, Wang Y, Liu Z, Wang Z, Tao C, Wu A . Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing. Cancer Med. 2024; 13(7):e7043. PMC: 10993708. DOI: 10.1002/cam4.7043. View

13.

Gu B, Bessler M, Mason P . A pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proc Natl Acad Sci U S A. 2008; 105(29):10173-8. PMC: 2481326. DOI: 10.1073/pnas.0803559105. View

14.

Hirata M, Fujita K, Fujihara S, Mizuo T, Nakabayashi R, Kono T . Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines. In Vivo. 2022; 36(1):94-102. PMC: 8765179. DOI: 10.21873/invivo.12680. View

15.

Llovet J, De Baere T, Kulik L, Haber P, Greten T, Meyer T . Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18(5):293-313. DOI: 10.1038/s41575-020-00395-0. View

16.

Shibata T . Genomic landscape of hepatocarcinogenesis. J Hum Genet. 2021; 66(9):845-851. DOI: 10.1038/s10038-021-00928-8. View

17.

Li W, Yan Y, Zheng Z, Zhu Q, Long Q, Sui S . Targeting the NCOA3-SP1-TERT axis for tumor growth in hepatocellular carcinoma. Cell Death Dis. 2020; 11(11):1011. PMC: 7689448. DOI: 10.1038/s41419-020-03218-x. View

18.

Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song M . Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell. 2023; 42(1):135-156.e17. DOI: 10.1016/j.ccell.2023.11.010. View

19.

Sullivan K, Galbraith M, Andrysik Z, Espinosa J . Mechanisms of transcriptional regulation by p53. Cell Death Differ. 2017; 25(1):133-143. PMC: 5729533. DOI: 10.1038/cdd.2017.174. View

20.

Takeshima H, Ushijima T . Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. NPJ Precis Oncol. 2019; 3:7. PMC: 6403339. DOI: 10.1038/s41698-019-0079-0. View